chronic health conditions
Moderna Wins Expanded FDA Approval for RSV Vaccine in At-Risk Younger Adults
Moderna; RSV vaccine; FDA approval; mRESVIA; at-risk adults; 18 to 59 years; expanded label; chronic health conditions
Actionable Insights Powered by AI
Moderna; RSV vaccine; FDA approval; mRESVIA; at-risk adults; 18 to 59 years; expanded label; chronic health conditions